Fundraising FoxMadison Vaccines
Madison, US · Founded 2012 · 1 known investors
Find your way into Madison Vaccines
Sign up to see every warm intro you have to Madison Vaccines
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Madison Vaccines team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Madison Vaccines Inc. (MVI) develops immunotherapies and therapeutic vaccines for prostate cancer, designed to be combined with standard-of-care treatments and checkpoint inhibitors across metastatic and non-metastatic stages. Its therapies target patients at all stages of prostate cancer to delay disease progression and enhance the effectiveness of PD-1 and AR axis inhibitors.
Founders & leadership
Madison Vaccines was founded in 2012 by Douglas G. McNeel, MD, PhD.
Board
Investors · 1
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 1 round · 2013
▶$2.4MraisedJan 2014 · 6 investors · PharmaceuticalsRule 506(b)
- Richard R. Lesniewski, PhDExecutive Officer, Director
- Douglas G. McNeel, MD, PhDExecutive Officer, Director
- Leigh CaganDirector
- Paul Weiss, PhDDirector
- Offering amount
- $9M
- Amount sold
- $2.4M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Madison Vaccines do?
- Madison Vaccines Inc. (MVI) develops immunotherapies and therapeutic vaccines for prostate cancer, designed to be combined with standard-of-care treatments and checkpoint inhibitors across metastatic and non-metastatic stages. Its therapies target patients at all stages of prostate cancer to delay disease progression and enhance the effectiveness of PD-1 and AR axis inhibitors.
- Who founded Madison Vaccines?
- Madison Vaccines was founded by Douglas G. McNeel, MD, PhD in 2012.
- Who are Madison Vaccines's investors?
- Madison Vaccines's investors include Clarevia Ventures.
- How much funding has Madison Vaccines raised?
- Madison Vaccines has disclosed $2.4M raised across 1 round.
- Where is Madison Vaccines headquartered?
- Madison Vaccines is headquartered in Madison, US.